Loading…
Immunome, Inc. is projected to rise to $30.01 by 2027, a +29% move from its current price of $23.35. IMNM is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $22.73 | $23.36 | $24.02 | +0.06% |
| Jul 14 | $22.48 | $23.38 | $24.30 | +0.11% |
| Jul 15 | $22.30 | $23.39 | $24.53 | +0.17% |
| Jul 16 | $22.15 | $23.40 | $24.73 | +0.23% |
| Jul 17 | $22.02 | $23.42 | $24.90 | +0.28% |
| Jul 18 | $21.90 | $23.43 | $25.06 | +0.34% |
| Jul 19 | $21.80 | $23.44 | $25.21 | +0.40% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $21.80 | $23.44 | $25.21 | +0.40% |
| Week 2 | $21.23 | $23.54 | $26.09 | +0.80% |
| Week 3 | $20.83 | $23.63 | $26.81 | +1.20% |
| Week 4 | $20.51 | $23.72 | $27.44 | +1.60% |
| Week 5 | $20.24 | $23.82 | $28.03 | +2.00% |
| Week 6 | $20.00 | $23.91 | $28.58 | +2.41% |
| Week 7 | $19.80 | $24.01 | $29.11 | +2.81% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Immunome, Inc. is a biotechnology company that engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical assets comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Immunome, Inc. (IMNM) is a healthcare asset with a current price of $23.61 and a market cap of $2.67B. It ranks 1806 by market cap. The current price and market position place Immunome among healthcare equities with a modest ranking given its market size.
A major floor 34.0% below — a decisive break under it would weaken the trend.
The nearest floor, 23.3% below — buyers have tended to step in here.
The nearest ceiling, 4.5% above — a clean break opens room to run.
A major ceiling 21.5% above — clearing it would confirm fresh momentum.
Key IMNM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IMNM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $23.96 | Sell | $23.55 | Sell |
| MA 10 | $22.71 | Buy | $22.76 | Buy |
| MA 20 | $20.74 | Buy | $21.73 | Buy |
| MA 50 | $21.12 | Buy | $21.27 | Buy |
| MA 100 | $21.49 | Buy | $21.07 | Buy |
| MA 200 | $20.20 | Buy | $19.53 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 63.76 | Neutral |
| Stoch RSI (14) | 63.48 | Neutral |
| CCI (20) | 84.91 | Neutral |
| Williams %R (14) | -19.96 | Info |
| MACD (12,26,9) | 0.51 | Buy |
| ROC (12) | 20.80 | Buy |
| Bollinger %B (20,2) | 0.79 | Neutral |
| Stochastic %K (14) | 80.04 | Sell |
| TRIX (15) | 0.30 | Buy |
| Awesome (5,34) | 3.34 | Buy |
| Ultimate (7,14,28) | 72.86 | Sell |
| Momentum (10) | 3.95 | Buy |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 24.54 | Sell |
| ADX (14) | 26.13 | Buy |
| ATR (14) | 0.53 | Info |
The 30-day picture is bullish, with sentiment labeled as BULLISH and RSI14 at 70. The stock’s technical posture is supported by the SMA50 at $21.07 and the SMA200 at $19.83. Near-term support sits at $17.91 and near-term resistance at $23.61. The 30-day price range spans from $19.33 to $28.84.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $17.91 | $23.35 | $31.08 | 0% | Neutral | |
| $23.87 | $30.01 | $39.93 | +29% | Bullish | |
| $30.39 | $39.30 | $54.27 | +68% | Bullish | |
| $34.90 | $46.19 | $65.67 | +98% | Bullish | |
| $37.26 | $50.35 | $73.35 | +116% | Bullish | |
| $37.32 | $51.39 | $76.48 | +120% | Bullish | |
| $41.76 | $58.51 | $88.77 | +151% | Bullish | |
| $47.82 | $68.10 | $105.13 | +192% | Bullish | |
| $54.32 | $78.58 | $123.25 | +237% | Bullish | |
| $63.28 | $92.92 | $147.93 | +298% | Bullish | |
| $90.12 | $141.62 | $239.89 | +506% | Bullish | |
| $141.70 | $250.24 | $464.03 | +972% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $17.91 | $23.35 | $27.99 | +0.00% |
| August 2026 | $20.64 | $24.37 | $29.56 | +4.37% |
| September 2026 | $20.68 | $24.59 | $30.15 | +0.89% |
| October 2026 | $19.97 | $23.89 | $29.58 | -2.82% |
| November 2026 | $19.98 | $24.03 | $29.98 | +0.58% |
| December 2026 | $20.47 | $24.73 | $31.08 | +2.90% |
Click any year to see its month-by-month IMNM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, IMNM could reach as high as $31.08, with a base case around $23.35 and support toward $17.91 — roughly 0% from $23.35. Price action looks broadly range-bound.
Expect IMNM to range from $23.87 to $39.93 through 2027. The $30.01 average target implies a +29% move from current prices. That is up +29% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The IMNM price prediction for 2028 points to an average of $39.30 (low $30.39, high $54.27) — a potential gain of +68% on today's $23.35. Momentum favours further upside here.
In 2029, IMNM is projected to trade between $34.90 and $65.67, averaging $46.19 — a potential gain of +98% from today's $23.35. That is up +18% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Immunome, Inc.'s 2030 outlook centres on $50.35, within a $37.26 to $73.35 range. That is up +9% on the projected 2029 average. That marks a +116% change versus current levels. Momentum favours further upside here.
By 2031, IMNM could reach as high as $76.48, with a base case around $51.39 and support toward $37.32 — roughly +120% from $23.35. Buyers look set to stay in control over this stretch.
Expect IMNM to range from $41.76 to $88.77 through 2032. The $58.51 average target implies a +151% move from current prices. That is up +14% on the projected 2031 average. Momentum favours further upside here.
The IMNM price prediction for 2033 points to an average of $68.10 (low $47.82, high $105.13) — a potential gain of +192% on today's $23.35. Buyers look set to stay in control over this stretch.
In 2034, IMNM is projected to trade between $54.32 and $123.25, averaging $78.58 — a potential gain of +237% from today's $23.35. That is up +15% on the projected 2033 average. Momentum favours further upside here.
Immunome, Inc.'s 2035 outlook centres on $92.92, within a $63.28 to $147.93 range. That is up +18% on the projected 2034 average. That marks a +298% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, IMNM could reach as high as $239.89, with a base case around $141.62 and support toward $90.12 — roughly +506% from $23.35. Momentum favours further upside here.
Expect IMNM to range from $141.70 to $464.03 through 2050. The $250.24 average target implies a +972% move from current prices. That is up +77% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in IMNM today (≈ 42.826552 IMNM) could be worth
$10,717.07
+$9,717.07 (+972%) by 2050 · US Dollar
Based on the average projected IMNM price of $250.24 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IMNMwould be worth at today's price.
$1,000 invested in IMNM on Jul 10, 2025 (≈ 111.731846 IMNM) would be worth
$2,608.94
+$1,608.94 (+160.9%) today · 2.61× · US Dollar
Based on a IMNM entry price of $8.95 vs. today's $23.35.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $23.61 | $988.99 | -1.1% |
| 1 month ago | $18.16 | $1,285.79 | +28.6% |
| 3 months ago | $21.67 | $1,077.53 | +7.8% |
| 6 months ago | $20.57 | $1,135.15 | +13.5% |
| 1 year ago | $8.95 | $2,608.94 | +160.9% |
| All time (5.0y) ago | $16.21 | $1,440.47 | +44.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IMNM forecast.
Our base-case forecast reaches $47.00 around 2030.
Implied market cap at $47.00: $5.32B
The multi-year forecast shows a strong upside trend with rising averages and notable ROIs. For 2026, the average price is $23.61 with a 0% ROI and a neutral sentiment. In 2027, the average is $30.71 with a 30.1% ROI and bullish sentiment.
In 2028, the average is $41.72 with a 76.7% ROI and bullish sentiment. In 2029, the average is $48.45 with a 105.2% ROI and bullish sentiment. By 2030, the average is $52.36 with a 121.8% ROI and bullish sentiment.
The trajectory continues through 2031 with an average of $54.30 (130% ROI), 2032 at $61.43 (160.2% ROI), 2033 at $71.92 (204.6% ROI), 2034 at $84.67 (258.6% ROI), and 2035 at $99.84 (322.9% ROI). By 2040 the average reaches $155.33 with a 557.9% ROI, and by 2050 the average is $268.33 with a 1036.5% ROI, all with bullish sentiment. These figures reflect estimates of future pricing and are not guarantees; outcomes depend on market and clinical development factors.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $52.36 with a min of $38.03 and a max of $77.92, and a ROI of 121.8% with bullish sentiment.
The forecast shows meaningful upside through 2050, with the average price rising to $268.33 and a ROI of 1036.5% by 2050, along with bullish sentiment in later years. These are estimates and not guarantees.
Yes, the 2035 forecast lists an average of $99.84 and a max of $163.44 (bullish). The max in 2035 exceeds 100, and later years show even higher maxima (e.g., 2040 max $271.73 and 2050 max $516.82).
The sentiment is BULLISH with RSI14 at 70. Key levels are SMA50 at $21.07 and SMA200 at $19.83, with near-term support at $17.91 and resistance at $23.61. The 30-day price range is $19.33 to $28.84.
Current price is $23.61 and market cap is $2.67B. The asset ranks 1806.
Immunome, Inc. Community Discussion
0Share your Immunome, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.